| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5626566 | NOVO NORDISK INC | Large dose pen |
May, 2014
(10 years ago) | |
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
|
US5626566 (Pediatric) | NOVO NORDISK INC | Large dose pen |
Nov, 2014
(9 years ago) | |
| US5693027 | NOVO NORDISK INC | Adaptor top |
Dec, 2014
(9 years ago) | |
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
|
US5693027 (Pediatric) | NOVO NORDISK INC | Adaptor top |
Jun, 2015
(8 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(10 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(19 days from now) | |
Novolog Penfill is owned by Novo Nordisk Inc.
Novolog Penfill contains Insulin Aspart Recombinant.
Novolog Penfill has a total of 10 drug patents out of which 9 drug patents have expired.
Expired drug patents of Novolog Penfill are:
- US5626566
- US5618913
- US5626566*PED
- US5693027
- US5618913*PED
- US5693027*PED
- US5866538
- US5866538*PED
- US8579869
Novolog Penfill was authorised for market use on 31 October, 2013.
Novolog Penfill is available in injectable;subcutaneous dosage forms.
The generics of Novolog Penfill are possible to be released after 23 May, 2024.
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG PENFILL family patents
